Caicun Zhou Selected Research

Exanthema (Rash)

1/2018	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial.
1/2018	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
1/2017	Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
1/2016	Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.
1/2016	Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.
2/2015	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
1/2015	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
2/2014	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
9/2013	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
5/2012	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caicun Zhou Research Topics

Disease

207	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 08/2004
137	Neoplasms (Cancer) 04/2022 - 08/2004
68	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2005
30	Disease Progression 10/2022 - 08/2004
29	Adenocarcinoma of Lung 05/2022 - 05/2012
26	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2005
21	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2015
19	Adenocarcinoma 01/2021 - 01/2006
14	Exanthema (Rash) 01/2018 - 07/2009
12	Brain Neoplasms (Brain Tumor) 01/2022 - 11/2014
11	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2012
8	Neutropenia 01/2022 - 07/2010
8	Pneumonia (Pneumonitis) 01/2022 - 05/2012
6	Diarrhea 10/2022 - 01/2015
5	Vomiting 01/2021 - 02/2014
5	Acne Vulgaris 01/2018 - 05/2012
5	Lymphoma (Lymphomas) 01/2018 - 08/2013
4	Carcinoma (Carcinomatosis) 01/2021 - 01/2018
4	Breast Neoplasms (Breast Cancer) 12/2020 - 12/2011
4	Circulating Neoplastic Cells 05/2020 - 08/2015
4	Interstitial Lung Diseases (Interstitial Lung Disease) 11/2019 - 10/2009
4	Febrile Neutropenia 03/2016 - 07/2010
3	Infections 10/2021 - 03/2008
3	Nausea 01/2021 - 04/2014
3	Hypoxia (Hypoxemia) 01/2021 - 02/2015
3	Stomatitis 01/2018 - 02/2014
3	Fatigue 07/2017 - 09/2014
3	Leukopenia 09/2014 - 07/2010
2	Genomic Instability 10/2021 - 04/2021
2	Bites and Stings (Sting) 10/2021 - 01/2020
2	Lymphatic Metastasis 01/2021 - 06/2016

Drug/Important Bio-Agent (IBA)

69	ErbB Receptors (EGF Receptor)IBA 05/2022 - 01/2006
65	Tyrosine Kinase InhibitorsIBA 05/2022 - 10/2010
40	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2018
31	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2011
23	PlatinumIBA 01/2022 - 08/2004
22	Gefitinib (Iressa)FDA Link 01/2021 - 08/2004
20	LigandsIBA 04/2022 - 10/2010
20	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 07/2009
16	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2007
15	Pharmaceutical PreparationsIBA 06/2020 - 01/2007
14	B7-H1 AntigenIBA 10/2021 - 01/2016
13	AfatinibIBA 01/2022 - 05/2012
12	Gemcitabine FDA Link 01/2022 - 08/2011
12	Pemetrexed (MTA)FDA Link 01/2021 - 12/2012
11	CrizotinibIBA 06/2021 - 03/2014
10	Anaplastic Lymphoma KinaseIBA 06/2021 - 11/2012
10	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2006
10	osimertinibIBA 12/2020 - 12/2014
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2016
8	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 08/2011
8	icotinibIBA 01/2021 - 09/2013
8	RNA (Ribonucleic Acid)IBA 01/2021 - 12/2010
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 03/2008
7	Monoclonal AntibodiesIBA 01/2022 - 01/2018
6	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2018
6	AntibodiesIBA 08/2021 - 02/2015
6	Bevacizumab (Avastin)FDA Link 12/2020 - 08/2010
6	Long Noncoding RNAIBA 01/2020 - 02/2015
6	Messenger RNA (mRNA)IBA 01/2018 - 12/2010
5	camrelizumabIBA 06/2022 - 01/2021
5	apatinibIBA 06/2022 - 01/2018
5	Docetaxel (Taxotere)FDA Link 02/2021 - 07/2010
5	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 01/2018
5	AntigensIBA 01/2021 - 01/2015
5	Peptides (Polypeptides)IBA 04/2020 - 10/2010
5	Alanine Transaminase (SGPT)IBA 01/2019 - 08/2011
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2018 - 01/2005
4	Liposomes (Liposome)IBA 01/2022 - 10/2010
4	Therapeutic UsesIBA 03/2021 - 08/2004
4	Biological ProductsIBA 02/2021 - 12/2015
4	MucinsIBA 02/2021 - 01/2018
4	Circulating Tumor DNAIBA 01/2021 - 11/2015
4	Cell-Free Nucleic AcidsIBA 01/2021 - 10/2016
4	CytokinesIBA 01/2021 - 08/2004
4	Folic Acid (Vitamin M)FDA LinkGeneric 05/2020 - 08/2015
4	VaccinesIBA 04/2020 - 04/2017
4	IntegrinsIBA 11/2018 - 01/2007
4	MicroRNAs (MicroRNA)IBA 08/2018 - 01/2017
4	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2017 - 08/2013
4	Transcription Factors (Transcription Factor)IBA 05/2017 - 01/2005
3	Programmed Cell Death 1 ReceptorIBA 04/2022 - 01/2021
3	Phosphotransferases (Kinase)IBA 02/2021 - 08/2013
3	Cancer VaccinesIBA 04/2020 - 11/2019
3	Contrast MediaIBA 11/2018 - 05/2011
3	Interleukin-6 (Interleukin 6)IBA 11/2018 - 08/2004
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 09/2016 - 01/2013
3	Codon (Codons)IBA 10/2010 - 01/2006
2	CreatinineIBA 10/2022 - 01/2012
2	Etoposide (VP 16)FDA LinkGeneric 01/2022 - 01/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2021 - 08/2018
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 10/2021 - 01/2020
2	InterferonsIBA 10/2021 - 01/2020
2	alectinibIBA 06/2021 - 01/2019

Therapy/Procedure

81	Drug Therapy (Chemotherapy) 06/2022 - 08/2004
79	Therapeutics 05/2022 - 02/2005
43	Immunotherapy 01/2022 - 06/2015
8	Radiotherapy 12/2020 - 10/2010
3	Molecular Targeted Therapy 10/2017 - 11/2014
2	Adjuvant Chemotherapy 10/2021 - 01/2015